Although smoking is a recognized risk factor for periodontitis ([@CIT0001]), leading to an increase in periodontal tissue destruction as a consequence of altered production of metalloproteinases (MMP), interleukins and inflammatory markers and host-cell function ([@CIT0002]--[@CIT0006]), biofilm still remains the primary etiologic factor for the development of destructive periodontal disease ([@CIT0001]). Thus, the primary goal of periodontal therapy is to target the subgingival biofilm present in periodontally-diseased sites, which is associated with the progressive destruction of the supportive periodontal tissues. It is well documented that conventional therapy, i.e. subgingival scaling and root planing, is effective in the achievement of this goal. Supragingival biofilm control has been shown to play a critical role in the success of periodontal therapy due to its impact on the subgingival biofilm and its inhibition of re-colonization ([@CIT0007]--[@CIT0009]). However, conflicting results regarding the impact of supragingival biofilm control on the composition of established subgingival biofilm in untreated periodontal sites are found in the literature ([@CIT0010]--[@CIT0014]).

Smoking has been implicated as a factor that reduces the effectiveness of treatment. Smokers show less favorable responses to various kinds of periodontal treatments, such as non-surgical, surgical, regeneration procedures, and mucogingival surgery ([@CIT0015]--[@CIT0017]). The mechanisms by which smoking affects the response to periodontal treatment might be related to the altered inflammatory and immune response that has been observed in smokers and/or to the persistence of pathogenic flora in smokers after treatment ([@CIT0002], [@CIT0018], [@CIT0019]). Studies have, therefore, aimed to document a possible role of smoking in the oral microbiota and, although no conclusive findings have been reported, some data have demonstrated that there are important differences in the composition of subgingival biofilm between smokers and non-smokers with chronic periodontal disease; which may, in fact, account for the lower response of smokers to therapy ([@CIT0020]--[@CIT0022]).

With the concepts discussed above in mind, there is an interest in the possible effect of supragingival biofilm control in the subgingival environment in untreated periodontitis sites in smokers. In smokers, in the only study available, supragingival periodontal therapy has been shown to affect the total bacterial load in the subgingival biofilm with a non-significant tendency towards lower amounts of recognized periodontal pathogens (*Aggregatibacter actinomycetemcomitans, Porphyromonas gingivalis* and *Tannerella forsythia*) in the treated sites ([@CIT0023]). However, in a recent and pioneer study in the field, Shchipkova et al. ([@CIT0024]) demonstrated that not only red complex bacteria, but several other uncultivated phylotypes, including 'unsuspicious' species in the subgingival biofilm, may play a role in the disease etiology, highlighting the necessity of expanding the analysis of the periodontal microbiome to open-ended techniques. As such, in the present study, it was hypothesized that supragingival therapy (ST), consisting of supragingival biofilm/calculus removal and dental surface polishing, removal of biofilm retainers, oral hygiene instruction, and reinforcement after 7 days, could affect subgingival biofilm biodiversity at sites with untreated severe chronic periodontitis in smokers. Microbiological analyses were performed using the non-culture-dependent 16S rRNA cloning and molecular sequencing. In addition, smokers and non-smokers were followed clinically with respect to the impact of the ST on the tissue stability.

Materials and methods {#S0001}
=====================

Ethics {#S20002}
------

This study was designed as a parallel, single-arm, and controlled study to evaluate the clinical and microbiological effects of ST on the biodiversity of subgingival biofilm collected in smokers and non-smokers with chronic periodontitis. Subjects included in the present study were examined, treated by ST, and re-evaluated 21 days later. The study was approved by the Institutional Review Board (IRB) and patients received a detailed description of the proposed treatment and gave their informed and written consent.

Patient selection and groups {#S20003}
----------------------------

Potential patients were selected from those referred to the Graduate Clinic of Piracicaba Dental School, University of Campinas -- UNICAMP, Brazil. All patients received a complete periodontal examination, including a full-mouth periodontal probing, radiographic examination and complete anamnesis.

The study inclusion criteria were:diagnosis of chronic periodontitis, according to the criteria of the 1999 International Classification ([@CIT0025]);presence of at least 20 teeth;at least nine teeth presenting probing pocket depth (PPD)≥5 mm with bleeding on probing (BoP; being at least two with PPD≥7 mm);\>35 years of age.

Patients who: (i) were pregnant or lactating; (ii) required antimicrobial pre-medication for the performance of periodontal examination and treatment; (iii) were suffering from any other systemic diseases (cardiovascular, pulmonary, liver, cerebral, or diabetes); (iv) had received antimicrobial treatment in the previous 3 months; (v) were taking long-term anti-inflammatory drugs; and/or (vi) had received a course of periodontal treatment within the last 6 months; were excluded from the study. A parallel, non-blinded and prospective study was designed to enroll the following two groups: *non-smoker group* (*n*=10): patients diagnosed with generalized and severe chronic periodontitis and that had never been smokers; and *smoker group* (*n*=10): patients diagnosed with generalized and severe chronic periodontitis and that had a smoking habit for at least 10 years and smoked at least 20 cigarettes per day. Sample size was determined by the Bioestat program, using a standard deviation of 1.0 and a power value of 80% to detect a difference between groups of 1.0 mm.

*Supragingival therapy (ST)*: After a full mouth examination and consent in participation, patients of both groups received a full mouth prophylaxis, supragingival calculus, and biofilm removal, using Gracey curettes, an ultrasonic scaler, bicarbonate spray and floss, or interdental brushes, according to the interdental space. Extraction of condemned teeth and biofilm retentive factors removal were also performed. The patients were also individually instructed on how to perform oral self-care, including the Bass technique, inter-dental flossing, and tongue brushing. All the subjects of the study received a standard fluoride dentifrice, toothbrushes, and floss as necessary; and were asked to perform complete oral self-care hygiene at least twice a day. A week after this first instruction session, patients returned to a reinforcement of oral self-care instructions. Twenty-one days after ST, clinical re-evaluation was performed and subgingival samples were collected for microbiological analysis. The same individual (DP) was trained to perform ST in all the patients, whereas another individual was trained to perform baseline and post-therapy clinical assessments (TM).

Clinical parameters {#S20004}
-------------------

The following clinical parameters were assessed immediately before therapy: full-mouth plaque index (FMPI), according to Ainamo and Bay ([@CIT0026]), and full-mouth bleeding score (FMBS), according to Mühlemann and Son ([@CIT0027]); these were calculated after assessing dichotomously the presence of dental biofilm at the site or BoP from the bottom of the pocket when probing with a manual probe.[1](#FN0001){ref-type="fn"} The percentage of total sites that revealed the presence of plaque or bleeding was calculated. All teeth presenting at least one site with PPD≥5 mm were selected for clinical evaluation. These teeth did not present pulpal disease or furcation lesion (in order to avoid bias). From those previously selected teeth, one site (the deepest one) was selected and followed-up during the experimental period, using an individually manufactured acrylic stent in which a groove was made to standardize the measurements. This selection resulted in a mean of 10.0±1.8 sites per patients evaluated during this study. For the sites selected, clinical parameters were:probing pocket depth (PPD -- distance from the bottom of the pocket to the margin);relative clinical attachment level (rCAL -- distance from the bottom of the pocket to the stent margin);relative gingival margin position (rGMP -- distance from the gingival margin to the stent margin).

All parameters were evaluated using a periodontal probe at baseline and 21 days after ST. The examinations were performed by a calibrated examiner (TM). For this calibration, three patients were selected and full mouth rCAL and PPD were measured, twice, within 24 hours, with at least 1 hour between the examinations. The intra-class correlation was calculated for each parameter, resulting in 93.5% reproducibility for rCAL and 94.3% for PPD.

Subgingival biofilm analysis {#S20005}
----------------------------

*Subgingival biofilm collection*: After a full-mouth examination, all sites previously selected for clinical follow-up were included in the subgingival biofilm analysis, as described. Following the careful removal of supragingival biofilm, the areas were washed with a water spray, isolated with cotton rolls and gently dried. A sterile paper point[2](#FN0002){ref-type="fn"} was inserted into the bottom of the periodontal pocket for 30 s. Each paper point was placed separately in sterile plastic tubes containing 0.01 M Tris EDTA solution, pH 8.0 (TE). DNA collection and extraction were performed as described by Casarin et al. ([@CIT0028]). For each patient, samples from the selected sites were pooled together to allow the 16S cloning sequencing.

*Cloning and sequencing*: First, the 16S rRNA gene was amplified using a universal primer set (27f and 1492r) as described by de Lillo et al. ([@CIT0029]). Cloning procedures were performed using a TOPO-TA cloning kit,[3](#FN0003){ref-type="fn"} following the manufacturer\'s instructions. Briefly, the amplicons resulting from universal amplification were cloned into *Escherichia coli* and then cultured overnight in Luria-Bertani (LB) plates (containing ampicilin and X-gal) for posterior colony selection. After colony selection, each colony was separately cultivated overnight, in LB broth media.[4](#FN0004){ref-type="fn"} The LB broth samples were then centrifuged to form a bacterial pellet containing *E. coli* that received vectors/bacterial DNA. After vector extraction, the products were purified[5](#FN0005){ref-type="fn"} and sequenced.[6](#FN0006){ref-type="fn"} After sequencing, a partial sequence of 600 bp was generated. These sequences were initially aligned and a similarity matrix was constructed from the alignments by the method of Jukes and Cantor ([@CIT0030]) (Bioedit 7.0 Program ([@CIT0031])). Phylogenetic trees were constructed by the neighbor joining method (Dotur Program ([@CIT0032])). Sequences were compared using the HOMD database ([@CIT0033]) applying a level of 98.5% sequence identity as cut-off. Sequences presenting 98% or greater similarity within a genus were considered as the same species.

Data management and statistical analysis {#S20006}
----------------------------------------

Clinical parameters were analyzed by Student\'s *t* test (for baseline intergroup comparisons) and repeated-measures ANOVA/Tukey (for clinical changes occurring after ST), using the PROC GLM procedure of the SAS program.[7](#FN0007){ref-type="fn"} For microbiological data, a variance-stabilizing transformation, described by Shchipkova et al. ([@CIT0024]), was used, promoting a normal distribution of the data. After data transformation, Mann--Whitney and Wilcoxon tests (for inter and intragroup analysis, respectively) were used for data analysis. For distribution and frequency analysis, the Chi-Square test was employed. A 5% level of significance was considered for clinical and microbiological data analysis.

Results {#S0007}
=======

Demographic and clinical data {#S20008}
-----------------------------

Demographic characteristics and baseline comparisons between groups are displayed in [Table 1](#T0001){ref-type="table"}. There were no statistical differences between groups regarding age or gender, as well as in relation to full mouth clinical parameters: plaque, BoP, periodontal probing depth, and clinical attachment level (*p*\>0.05). [Table 2](#T0002){ref-type="table"} illustrates the effect of ST on the clinical parameters assessed in the selected sites (PPD≥5 mm). At baseline, intergroup analysis (i.e. non-smokers vs. smokers) showed no significant differences for any of the parameters assessed (*p*\>0.05). The same results were seen after ST, with no differences between the groups (*p*\>0.05). In contrast, intragroup analysis (i.e. baseline vs.after ST, within the same experimental group) demonstrated that ST led to a significant reduction in PI, PPD, and rCAL (*p*\<0.05); whereas no significant changes were found with respect to BoP and GMP, in smokers and non-smokers (*p*\>0.05).

###### 

Clinical and demographic characteristics of participants at baseline (mean±standard deviation)

  Characteristics                               Non-smokers (*n=*10)   Smokers (*n=*10)
  --------------------------------------------- ---------------------- ------------------
  Age (mean/range)                              45.6±4.8               43.4±7.4
  \% males                                      50%                    55.6%
  FMPI (%)                                      79.7%±0.1              73.0%±0.2
  FMBOP (%)                                     76.8%±0.1              78.0%±0.2
  FMPPD (mm)                                    3.2±0.5                3.5±0.6
  FMCAL (mm)                                    3.9±0.8                4.3±0.8
  Tobacco exposure (number of cigarettes/day)   0±0                    20.8±3.5\*

Notes: FMPI, full mouth plaque index; FMBOP, full mouth bleeding on probing; FMPPD, full mouth periodontal probing depth; FMCAL, full mouth clinical attachment.

\*Indicates intergroup difference by Student\'s *t* test, *p*\<0.05. level.

###### 

Clinical parameters in smokers and non-smokers, at baseline and after supragingival therapy (ST), at the selected sites

              Non-smokers   Smokers                  
  ----------- ------------- ------------- ---------- -------------
  PI (%)      89.2±0.1      63.0±0.2\*    89.2±0.1   68.3±0.2\*
  BoP (%)     96.0±0.1      91.1±0.1      91.7±0.1   84.2±0.1
  PPD (mm)    4.9±0.2       4.3±0.6\*\*   5.0±0.8    4.4±0.6\*\*
  CALr (mm)   8.6±1.1       8.3±1.1\*     9.1±1.0    8.7±0.9\*
  GMP (mm)    3.7±1.1       4.0±1.1       4.1±0.6    4.3±0.5

Notes: ST, supragingival therapy; PI, plaque index; BoP, bleeding on probing; PPD, periodontal probing depth; CALr, clinical attachment level relative; GMP, gingival margin position.

Statistical difference between baseline and ST within groups (repeated measures ANOVA followed by Tukey test, \**p*\<0.05, \*\**p*\<0.01).

Microbiological data {#S20009}
--------------------

In total, 1,800 clones were identified, representing 78 different species in non-smoker subjects at baseline and 73 after ST, whereas in smokers 71 species were identified at baseline and 70 were observed after ST. [Table 3](#T0003){ref-type="table"} depicts the distribution of clones in the phylum and cultivation status (cultivated and not-yet-cultivated). There was no difference in phylum distribution between smokers and non-smokers, neither at baseline nor after ST. In regards to cultivation status, non-smoker subjects presented a higher prevalence of cultivated indexes compared with smokers at baseline, and at after ST (*p*\<0.05). In addition, 21 days after ST, an increase in cultivated phylotypes was seen only in non-smokers (*p*\<0.05).

###### 

Distribution by phylum (total number of clones) and culture condition (% of cultivated and not-yet-cultivated phylotypes) in smokers and non-smokers, at baseline and after supragingival therapy (ST)

                             Non-smokers   Smokers        
  -------------------------- ------------- --------- ---- ----
  Actinobacteria             3             4         1    3
  Bacteroidetes              13            14        16   21
  Firmicutes                 27            24        22   19
  Fusobacteria               6             4         11   6
  Proteobacteria             8             12        6    5
  Spirochaetes               11            6         8    9
  Synergistetes              10            9         7    7
  Total number of clones     78            73        71   70
  \% of cultivated\*^†^      61.5          77^\#^    36   40
  \% of not-yet-cultivated   38.5          23        64   60

Notes: ST, supragingival therapy.

\*Indicates intergroup difference at baseline; ^†^indicates intergroup difference after ST; ^\#^indicates intragroup difference (Chi-Square test, *p*\<0.05).

[Figure 1](#F0001){ref-type="fig"} illustrates the distribution of 16S clonal analysis by genera in non-smokers and smokers, before and after ST. As noted, at baseline, smokers demonstrated significantly greater levels of the genera *Fusobacterium* and *Bacteroides*, whereas non-smokers presented higher levels of *Eubacterium, Synergistes*, and *Streptococcus* (Chi-Square test, *p*\<0.05).

![Distribution by genus (percent total clones) in smokers and non-smokers, at baseline and after supragingival therapy (ST). \*Indicates intergroup differences at baseline; ^†^indicates intergroup differences after ST; ^\#^indicates intragroup differences after ST (Chi-Square test, *p*\<0.05).](JOM-4-8640-g001){#F0001}

Moreover, ST altered the genera distribution in both groups. In non-smokers, a significant reduction in some genera such as *Eubacterium, Filifactor, Tannerella, Treponema*, and *Fusobacterium* was observed, whereas only *Filifactor* and *Fusobacterium* were reduced in smokers after ST (*p*\<0.05). The difference in genera distribution was still observed after ST, where *Streptococcus* was more present in non-smokers (*p*\<0.05) and *Bacteroides* and *Porphyromonas* were found more in smokers (*p*\<0.05).

The 20 most detected phylotypes were analyzed separately with regard to their frequency and proportions in the subgingival biofilm ([Table 4](#T0004){ref-type="table"}). Significant differences were observed in levels of certain species between current and never-smokers. Smokers presented higher levels of *Fusobacterium nucleatum* ss. *vincentii* and *Bacteroidetes* \[G-2\] sp. ∣Oral Taxon 274∣ Clone AU126 (*p*\<0.05), whereas non-smokers showed higher levels of *Streptococcus constellatus* and *Eubacterium* \[11\]\[G-6\] *nodatum* Oral Taxon 694. Moreover, Supragingival Therapy led to a more expressive alteration in the subgingival composition in non-smokers. Twenty-one days after ST, non-smokers presented lower levels of *Filifactor alocis, T. forsythia, Eubacterium* \[XI\]\[G-5\] *saphenum ∣* Oral Taxon 759 and *Eubacterium* \[XI\]\[G-3\] *brachy* (*p*\<0.05), whereas only *T. forsythia* presented a significant reduction after ST. Interestingly, a significant increase in *Synergistetes* \[G-3\] sp. Oral Clone BH017 and *Porphyromonas endodontalis* Oral Clone AJ002 was observed in smokers after ST (*p*\<0.05), highlighting the dissimilarities between smokers and non-smokers with regards to their microbial profile.

###### 

Top 20 most detected phylotype proportions (x value mean) in smokers and non-smokers, at baseline and after supragingival therapy

                                                                 Non-smokers   Smokers           
  -------------------------------------------------------------- ------------- ---------- ------ ----------
  *Filifactoralocis*                                             0.14          0.06^\#^   0.11   0.05^\#^
  *Tannerella forsythia*                                         0.09          0.03\#     0.09   0.06
  *Porphyromonas gingivalis*                                     0.10          0.07       0.06   0.04
  *Eubacterium* \[XI\]\[G-5\] *saphenum* ∣ Oral Taxon 759        0.09          0.01\#     0.07   0.05
  *Fusobacterium nucleatum ss.vincentii*                         0.01          0.00       0.05   0.01
  *Bacteroidetes* \[G-2\] sp. ∣ Oral Taxon 274 ∣ Clone AU126\*   0.00          0.00       0.03   0.04
  *Parvimonas micra*                                             0.02          0.02       0.03   0.02
  *Porphyromonas endodontalis* Oral Clone BB134                  0.02          0.02       0.03   0.04
  *Porphyromonas endodontalis* Oral Clone P2PB_52                0.02          0.00\#     0.03   0.03
  *Fusobacterium* sp. Oral Clone FL002                           0.01          0.00       0.03   0.01
  *Eubacterium* \[XI\]\[G-3\] brachy                             0.03          0.01\#     0.03   0.01
  *Peptostreptococcus stomatis*                                  0.00          0.00       0.02   0.01
  *Synergistetes* \[G-3\] sp. Oral Clone BH017^†^                0.04          0.02       0.03   0.06\#
  *Porphyromonas endodontalis* Oral Clone AJ002^†^               0.02          0.02       0.02   0.08\#
  *Treponema* sp. Oral Clone P4GB_42                             0.00          0.00       0.01   0.01
  *Sphingomonas* sp. Oral Taxon 006 ∣ Clone FI012                0.03          0.01       0.00   0.00
  *Streptococcus constellatus*\*                                 0.03          0.01       0.00   0.01
  *Eubacterium* \[11\]\[G-6\] *nodatum* Oral Taxon 694\*         0.06          0.05       0.01   0.01
  *Fusobacterium naviforme*                                      0.01          0.01       0.01   0.02
  *Treponema medium*                                             0.02          0.01       0.01   0.01

Notes: ST, supragingival therapy

\*Indicates statistical difference between non-smokers and smokers at baseline; ^†^indicates statistical difference between non-smokers and smokers after ST; ^\#^indicates statistical difference between baseline and after ST within group (Mann--Whitney and Wilcoxon tests, *p*\<0.05).

Discussion {#S0010}
==========

The habit of smoking has been reported to negatively affect periodontal tissues, cell defense, and host response. In addition, microbiological evaluations also indicate a possible influence on subgingival microflora. However, very limited information is available with respect to the effect of ST on the biodiversity of the subgingival biofilm in smokers with chronic periodontitis. With this in mind, it was hypothesized that ST, consisting of standard methods used for supragingival biofilm removal and control, including supragingival biofilm/calculus removal and dental surface polishing, removal of biofilm retainers, oral hygiene instruction and reinforcement after 7 days, would affect subgingival biofilm profile in smokers with severe chronic periodontitis. Subgingival biofilm biodiversity was assessed by the 16S gene cloning technique and clinical parameters were also used to illustrate clinical conditions at baseline and after ST in smokers and non-smokers. Data analyses demonstrated that: (i) there were significant differences in the subgingival biofilm composition, at baseline, in smokers versus non-smokers; (ii) subgingival biodiversity was significantly affected by ST in non-smokers, whereas only a slight effect was observed for smokers; and (iii) clinical response was not affected by dissimilar microbiological outcomes to ST in smokers versus non-smokers.

With non-surgical subgingival therapy as the main treatment modality, most authors report greater reductions in probing depth in non-smokers, compared with smokers ([@CIT0019], [@CIT0034]--[@CIT0038]). It is, therefore, important to note that there is substantial evidence for the clinical improvement in smokers after treatment, indicating that smoking, as a risk factor, will compromise rather than prevent tissue healing. In non-smokers, ST results in a reduction in gingival bleeding, probing depth, and a gain in attachment level ([@CIT0007], [@CIT0009], [@CIT0013], [@CIT0014], [@CIT0039], [@CIT0040]). In smokers, however, there was a lack of information on the impact of ST on the periodontal tissues at untreated sites.

Gomes et al., in 2007 ([@CIT0040]), were the only group to assess the changes in periodontal tissues after a supragingival periodontal therapy. In their study, ST consisted of supragingival calculus removal with hand curettes, extractions, endodontic treatment, placement of temporary restorations, and prostheses. Similarly to the findings of the present study, Gomes et al. ([@CIT0040]) demonstrated that a comparable clinical outcome was reached for smokers and non-smokers regardless of the severity of the disease. Both groups featured a reduction in plaque and bleeding indices, as well as a reduction in probing depth, and gain in clinical attachment level after 30 days of ST, which was maintained for up to 180 days ([@CIT0040]). In addition, as previously reported by others, in the present study, data analyses demonstrated that smokers presented a lower reduction in plaque index (PI) than non-smokers. Moreover, as expected, deep pockets presented only a mild change after ST: only a discrete reduction in BoP index was observed in smokers and non-smokers. In summary, available clinical data suggest that smokers and non-smokers with severe chronic periodontitis may similarly benefit from ST.

In the present study, we aimed to determine whether or not ST affected subgingival biofilm biodiversity in both groups. Often, studies have focused on assessing, in smoking and non-smoking conditions, the effect of periodontal therapy on genera associated with periodontal disease, including *P. gingivalis*, *Treponema denticola*, and *T. forsythia* ([@CIT0007], [@CIT0011], [@CIT0012], [@CIT0041], [@CIT0042]). However, an important study demonstrated that tobacco might also affect the levels of genera not always associated with periodontal disease ([@CIT0024]). In the present study, using an open-ended approach, a comparison between the subgingival biofilm composition of smokers and non-smokers at baseline (before ST), revealed a higher presence of certain genera, such as *Fusobacterium* (genus associated with periodontal disease) and *Bacteroides*; and lower levels of *Streptococcus, Synergistes*, and *Eubacterium*. These findings seem to confirm that tobacco exposure may lead to a subgingival biofilm composed not only in a higher proportion by pathogens associated with periodontal disease, but also some species, not commonly included as periodontal pathogens in target-ended or selective techniques.

However, in addition to presenting a reduction in 'health-associated' biofilm and an increase in 'disease-associated' biofilm, in the present study, smokers showed a lower response to ST, compared with non-smoker subjects as regards the microbiological composition of the subgingival biofilm. Non-smokers had a significant reduction in five species commonly associated with periodontal disease following ST, whereas in smokers only the levels of *F. alocis* were significantly reduced. In addition, after ST in smokers, disease-associated species, including *P. endodontalis*, were found to be increased.

*P. endodontali*s has been listed as one of the potential 'new species' associated with periodontal disease ([@CIT0043]), and the fact that *P. endodontali*s has additionally been shown to be reduced in subgingival biofilm when the smoking habit is given up ([@CIT0044]), suggesting this species as an important factor that might contribute to the pathogenesis of periodontal disease in smokers. The apparent reduction in some species in the subgingival biofilm after ST may be explained by the intimate relationship between both supra- and subgingival environments ([@CIT0045]), and also as a result of the mild, but statistically significant, clinical benefits promoted by ST after 21 days. The probing depth reduction may have led to significant changes in nutrients, oxygen, and microorganisms disposable in periodontal pockets, altering subgingival microflora. Moreover, the reduced microbiological effect of ST on smoker-subgingival microbiota, has been a common goal in previous studies. Furthermore when subgingival scaling and root planing are performed, smokers appear to remain positive for periodontitis-associated species, including *P. gingivalis*, *T. denticola*, *T. forsythia, P. intermedia, F. nucleatum*, and *Parvimonas micra* ([@CIT0041], [@CIT0046], [@CIT0047]). Therefore, after ST performance and the assessment of baseline and follow-up parameters, all the patients enrolled in this study were then treated by the conventional subgingival scaling and root planing approach.

In conclusion, in smokers, ST only slightly affected the subgingival biofilm biodiversity, as compared with non-smokers. However, clinically, the response in smokers and non-smokers was similar regardless of the differential impact of ST on the subgingival biofilm composition in these groups of patients.
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